...
首页> 外文期刊>Journal of Medicinal Chemistry >Structural and enzymatic analyses reveal the binding mode of a novel series of francisella tularensis enoyl reductase (FabI) inhibitors
【24h】

Structural and enzymatic analyses reveal the binding mode of a novel series of francisella tularensis enoyl reductase (FabI) inhibitors

机译:结构和酶学分析揭示了一系列新型土拉弗朗西斯菌烯酰还原酶(FabI)抑制剂的结合模式

获取原文
获取原文并翻译 | 示例

摘要

Because of structural and mechanistic differences between eukaryotic and prokaryotic fatty acid synthesis enzymes, the bacterial pathway, FAS-II, is an attractive target for the design of antimicrobial agents. We have previously reported the identification of a novel series of benzimidazole compounds with particularly good antibacterial effect against Francisella tularensis, a Category A biowarfare pathogen. Herein we report the crystal structure of the F. tularensis FabI enzyme in complex with our most active benzimidazole compound bound with NADH. The structure reveals that the benzimidazole compounds bind to the substrate site in a unique conformation that is distinct from the binding motif of other known FabI inhibitors. Detailed inhibition kinetics have confirmed that the compounds possess a novel inhibitory mechanism that is unique among known FabI inhibitors. These studies could have a strong impact on future antimicrobial design efforts and may reveal new avenues for the design of FAS-II active antibacterial compounds.
机译:由于真核和原核脂肪酸合成酶之间在结构和机制上的差异,细菌途径FAS-II是设计抗微生物剂的有吸引力的目标。我们以前曾报道过鉴定出一系列新的苯并咪唑化合物,这些化合物对图拉弗朗西斯菌(A类生物战病原体)具有特别良好的抗菌作用。在这里,我们报告与我们最活跃的苯并咪唑化合物与NADH结合的复杂的F. tularensis FabI酶的晶体结构。该结构表明,苯并咪唑化合物以独特的构象与底物位点结合,该构象不同于其他已知FabI抑制剂的结合基序。详细的抑制动力学已证实该化合物具有新颖的抑制机制,在已知的FabI抑制剂中是独特的。这些研究可能会对未来的抗菌设计工作产生重大影响,并可能为设计FAS-II活性抗菌化合物提供新途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号